TLV is tasked with carrying out health economic assessments of new drugs against cancer

4 July 2023 - The TLV shall carry out health economic assessments of new drugs to be used in clinics, ...

Read more →

Imbruvica is included in the high-cost protection with a changed benefit limitation

19 June 2023 - Ibrutinib (Imbruvica)140 mg, 280 mg & 420 mg tablets are now subsidised for the treatment ...

Read more →

More measures are needed to curb the development cost of pharmaceuticals

16 June 2023 - There are more and more new drugs, and more people are receiving treatment for their illnesses. At ...

Read more →

Health economic assessment of Carvykti in the treatment of multiple myeloma

16 June 2023 - TLV has prepared a health economic assessment for the regions for Carvykti (ciltacabtagene autoleucel). ...

Read more →

Health economic assessment of Pluvicto in advanced prostate cancer

12 June 2023 - TLV has produced a health economic assessment for the regions for Pluvicto (Lutetium Lu 177 vipivotide tetraxetan).  ...

Read more →

The Supreme Administrative Court did not test Mayzent

12 June 2023 - The Supreme Administrative Court decided on 3 May not to grant a review permit for Mayzent.  ...

Read more →

The FINOSE collaboration is extended and strengthened by the entry of the Danish Medicines Council

11 May 2023 - On 10 May 2023, the Nordic HTA collaboration FINOSE was extended for another three years and the ...

Read more →

TLV has decided on an increase in ceiling prices

12 April 2023 - TLV has decided to increase ceiling prices in certain package size groups. The decision to raise ceiling ...

Read more →

TLV reconsiders the subsidy of Lumykras (sotorasib)

4 April 2023 - TLV has started a review of Lumykras (sotorasib). Lumykras (sotorasib) has already been included in the high-cost ...

Read more →

Survey on patients' access to medicines for the treatment of rare health conditions

31 March 2023 - The TLV has submitted an interim report to the government for the task of proposing how ...

Read more →

Clarification on the subsidy limitation for drugs for diabetes

28 March 2023 - The TLV has clarified the subsidy limitation for all GLP-1 receptor agonists.  ...

Read more →

Final reconciliation of savings from side agreements for the full year 2022

28 March 2023 - The TLV has presented the Government with the final reconciliation of the outcome of savings from ...

Read more →

TLV is preparing for an increase in ceiling prices

17 March 2023 - In order to ensure continued good access to medicines for patients, TLV started in the autumn of ...

Read more →

Health economic assessment of Kimmtrak in disseminated ocular melanoma

16 February 2023 - The assessment applies to Kimmtrak as the sole treatment for adult patients with melanoma in the ...

Read more →

TLV proposes a new process for health economic assessments that are made in a short time and under special circumstances

1 February 2023 - In a report to the government, the Dental and Pharmaceutical Benefits Agency, TLV, presents experiences and lessons ...

Read more →